期刊文献+

血清CA125、CEA、AFP联合检测在卵巢肿瘤诊断中的价值 被引量:14

Diagnostic Value of Determination of Serum CA125,CEA and AFP in Patients with Ovarian Tumors
下载PDF
导出
摘要 目的 :探讨血清 CA1 2 5、CEA和 AFP联合检测在卵巢肿瘤诊断中的价值。方法 :采用酶联免疫分析法 ( EL ISA)对卵巢恶性肿瘤、良性肿瘤及子宫内膜异位症患者血清CA1 2 5、CEA及 AFP含量进行检测。结果 :卵巢恶性肿瘤患者 CA1 2 5含量明显高于对照组、卵巢良性肿瘤及交界性瘤 ( P<0 .0 1 ) ;子宫内膜异位症及盆腔炎患者 CA1 2 5含量高于对照组及卵巢良性肿瘤 ( P<0 .0 5 ) ;卵巢恶性肿瘤患者 CA1 2 5含量高于子宫内膜异位症 ( P<0 .0 5 )。结论 :单项检测 CA1 2 5对卵巢上皮性癌诊断性能最佳 ,对子宫内膜异位症也有较理想的诊断价值 ,CA1 2 5、CEA及 AFP联合检测对卵巢恶性肿瘤的诊断无明显价值 。 Objective:To study the diagnostic value of combined measurement of the cancer antigen 125 (CA125), CEA and AFP in patients with ovarian tumors. Methods:ELISA was used to measure the levels of serum CA125,CEA and AFP in patients with benign ovarian tumor, malignant ovarian tumor and endometriosis as well as normal controls. Results:Serum CA125 level was significantly higher in patients with malignant ovarian tumor than that in those with benign or borderline ovarian tumor and in control group(P<0.01). Serum CA125 level was higher in patients with endometriosis and pelvic infection than that in those with benign ovarian tumor and in control group(P<0.05).It was higher in patients with malignant ovarian tumor than that in those with endometriosis(P<0.05). Conclusion:The single detection of CA125 may be the best method of diagnosing ovarian epithelioma, and the detection of AFP has greater value in diagnosing malignant germ cell tumor.
出处 《陕西医学杂志》 CAS 北大核心 2004年第5期426-428,共3页 Shaanxi Medical Journal
关键词 血清 CA125 CEA AFP 联合检测 卵巢肿瘤 诊断 Ovarian reoplasms/diagnosis Carcinoembryonic antigen/diagnostic use Alpha fetoproteins/diagnostic use Cancer antigen 125/diagnostic use
  • 相关文献

参考文献7

二级参考文献16

  • 1吉本秋雄.实用临床检查[M].台北:广思医学开发科研中心,1993.128-128.
  • 2许一平 郑捷.现代免疫学检验与临床实践[M].上海:上海科学技术文献出版社,1999.350-350.
  • 3[1]Robert C,Bast JR,Thomas L,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer [J ]. New Engl J Med, 1983, 309(15) :883.
  • 4[2]Alvarez RD, To A, Boots LR, et al. CA125 as a serum maker for poor prognosis in ovarianmalignancies[J]. Gynecol Oncol, 1987,26(3) :284.
  • 5[3]Hoffman L. CA125 monitoring in the evaluation of the course and prognosis of metastasizing ovarian carcinoma.In: Rainer Klapdor (ed) New tumor maker and their monoclonal antibodies [ M ]. New York: Geory Thieme Verlag Stuttgar, 1988:142.
  • 6[4]Fleuren GL, Nap M, Aalders JL, et al.Explanation of the limited correlation between tumor CA125 content and serum CA125 antigen levels in patients with ovarian tumors[J]. Cancer, 1987,60(10) :2437.
  • 7[5]Nakai T, Endo K, Hosono M, et al. Drug effect on CA125 antigen expression and antibody binding to cancer cells[J]. Int J Cancer, 1991,48 (3): 463.
  • 8[6]Maughan TS,Fish RG,Shelly M ,et al. Antigen CA125in tumor tissue and serum from patients with adenocarcinoma of the ovary[J ]. Gynecol Oncol, 1988,30(3) :342.
  • 9[7]Jasani B,Edwards RE,Thomas ND ,et al. The use of vimentin antibodies in the diagnosis of malignant mesothelioma[J]. virchows Arch, 1985,406(4) :441
  • 10[8]Robert C,Bast JR,Thomas L,et al. Monitoring human ovarian carcinoma with a combination of CA125、CA19-9、CEA[J]. Am J Obstet Gynecol, 1984,149(5) :553.

共引文献42

同被引文献116

引证文献14

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部